^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CyPep-1

i
Other names: CyPep-1, CY-101
Associations
Company:
Cytovation
Drug class:
Immunomodulator, Axin2 activator
Related drugs:
Associations
3ms
Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
P1/2, N=6, Completed, Cytovation AS | Active, not recruiting --> Completed | N=90 --> 6 | Trial completion date: Feb 2025 --> Sep 2024
Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
5ms
CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
P1/2, N=60, Completed, Cytovation AS | Active, not recruiting --> Completed | Trial primary completion date: Mar 2024 --> Jul 2024
Trial completion • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
Keytruda (pembrolizumab) • CyPep-1
12ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
1year
Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
P1/2, N=90, Active, not recruiting, Cytovation AS | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2
Enrollment closed • Phase classification • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
over1year
CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
P1/2, N=75, Active, not recruiting, Cytovation AS | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
almost2years
Enrollment open • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
over2years
New P1/2 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • CyPep-1
over2years
CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
P1/2, N=75, Recruiting, Cytovation AS | N=45 --> 75 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1